Selected research
Market Structure
Global Rifapentine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Rifapentine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Rifapentine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Rifapentine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rifapentine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Rifapentine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Rifapentine include Changzheng Pharma, Sine Pharma, Sanofi, MED-SHINE and Foutune Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Rifapentine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Rifapentine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Rifapentine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rifapentine market size, projected growth trends, production technologies, key applications, and end-use industries.
Rifapentine Segment by Company
Changzheng Pharma
Sine Pharma
Sanofi
MED-SHINE
Foutune Pharma
Rifapentine Segment by Type
20 Capsules/Box
24 Capsules/Box
Rifapentine Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Rifapentine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifapentine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rifapentine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifapentine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Rifapentine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rifapentine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rifapentine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Rifapentine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 20 Capsules/Box
- 24 Capsules/Box
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Changzheng Pharma
- Sine Pharma
- Sanofi
- MED-SHINE
- Foutune Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Rifapentine Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Rifapentine Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Rifapentine Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Rifapentine Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Rifapentine Market Dynamics
- 2.1 Rifapentine Industry Trends
- 2.2 Rifapentine Industry Drivers
- 2.3 Rifapentine Industry Opportunities and Challenges
- 2.4 Rifapentine Industry Restraints
3 Rifapentine Market by Manufacturers
- 3.1 Global Rifapentine Revenue by Manufacturers (2021-2026)
- 3.2 Global Rifapentine Sales by Manufacturers (2021-2026)
- 3.3 Global Rifapentine Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Rifapentine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Rifapentine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Rifapentine Manufacturers, Product Type & Application
- 3.7 Global Rifapentine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Rifapentine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Rifapentine Players Market Share by Revenue in 2025
- 3.8.3 2025 Rifapentine Tier 1, Tier 2, and Tier 3
4 Rifapentine Market by Type
- 4.1 Rifapentine Type Introduction
- 4.1.1 20 Capsules/Box
- 4.1.2 24 Capsules/Box
- 4.2 Global Rifapentine Sales by Type
- 4.2.1 Global Rifapentine Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Rifapentine Sales by Type (2021-2032)
- 4.2.3 Global Rifapentine Sales Market Share by Type (2021-2032)
- 4.3 Global Rifapentine Revenue by Type
- 4.3.1 Global Rifapentine Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Rifapentine Revenue by Type (2021-2032)
- 4.3.3 Global Rifapentine Revenue Market Share by Type (2021-2032)
5 Rifapentine Market by Application
- 5.1 Rifapentine Application Introduction
- 5.1.1 Retail Pharmacies
- 5.1.2 Online Pharmacies
- 5.1.3 Hospital Pharmacies
- 5.2 Global Rifapentine Sales by Application
- 5.2.1 Global Rifapentine Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Rifapentine Sales by Application (2021-2032)
- 5.2.3 Global Rifapentine Sales Market Share by Application (2021-2032)
- 5.3 Global Rifapentine Revenue by Application
- 5.3.1 Global Rifapentine Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Rifapentine Revenue by Application (2021-2032)
- 5.3.3 Global Rifapentine Revenue Market Share by Application (2021-2032)
6 Global Rifapentine Sales by Region
- 6.1 Global Rifapentine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Rifapentine Sales by Region (2021-2032)
- 6.2.1 Global Rifapentine Sales by Region (2021-2026)
- 6.2.2 Global Rifapentine Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Rifapentine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Rifapentine Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Rifapentine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Rifapentine Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Rifapentine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Rifapentine Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Rifapentine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Rifapentine Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Rifapentine Revenue by Region
- 7.1 Global Rifapentine Revenue by Region
- 7.1.1 Global Rifapentine Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Rifapentine Revenue by Region (2021-2026)
- 7.1.3 Global Rifapentine Revenue by Region (2027-2032)
- 7.1.4 Global Rifapentine Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Rifapentine Revenue (2021-2032)
- 7.2.2 North America Rifapentine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Rifapentine Revenue (2021-2032)
- 7.3.2 Europe Rifapentine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Rifapentine Revenue (2021-2032)
- 7.4.2 Asia-Pacific Rifapentine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Rifapentine Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Rifapentine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Changzheng Pharma
- 8.1.1 Changzheng Pharma Company Information
- 8.1.2 Changzheng Pharma Business Overview
- 8.1.3 Changzheng Pharma Rifapentine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Changzheng Pharma Rifapentine Product Portfolio
- 8.1.5 Changzheng Pharma Recent Developments
- 8.2 Sine Pharma
- 8.2.1 Sine Pharma Company Information
- 8.2.2 Sine Pharma Business Overview
- 8.2.3 Sine Pharma Rifapentine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sine Pharma Rifapentine Product Portfolio
- 8.2.5 Sine Pharma Recent Developments
- 8.3 Sanofi
- 8.3.1 Sanofi Company Information
- 8.3.2 Sanofi Business Overview
- 8.3.3 Sanofi Rifapentine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sanofi Rifapentine Product Portfolio
- 8.3.5 Sanofi Recent Developments
- 8.4 MED-SHINE
- 8.4.1 MED-SHINE Company Information
- 8.4.2 MED-SHINE Business Overview
- 8.4.3 MED-SHINE Rifapentine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 MED-SHINE Rifapentine Product Portfolio
- 8.4.5 MED-SHINE Recent Developments
- 8.5 Foutune Pharma
- 8.5.1 Foutune Pharma Company Information
- 8.5.2 Foutune Pharma Business Overview
- 8.5.3 Foutune Pharma Rifapentine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Foutune Pharma Rifapentine Product Portfolio
- 8.5.5 Foutune Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Rifapentine Value Chain Analysis
- 9.1.1 Rifapentine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Rifapentine Production Mode & Process
- 9.2 Rifapentine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Rifapentine Distributors
- 9.2.3 Rifapentine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst